Nicox (LTS:0RCQ) Days Payable : 0.00 (As of Jun. 2024)

View and export this data going back to 2008. Start your Free Trial

What is Nicox Days Payable?

Nicox's average Accounts Payable for the six months ended in Jun. 2024 was €2.04 Mil. Nicox's Cost of Goods Sold for the six months ended in Jun. 2024 was €0.00 Mil.

The historical rank and industry rank for Nicox's Days Payable or its related term are showing as below:

LTS:0RCQ' s Days Payable Range Over the Past 10 Years
Min: 46.67 Med: 591.43 Max: 1642.5
Current: 53.16

During the past 13 years, Nicox's highest Days Payable was 1642.50. The lowest was 46.67. And the median was 591.43.

LTS:0RCQ's Days Payable is ranked worse than
70.03% of 714 companies
in the Biotechnology industry
Industry Median: 127.37 vs LTS:0RCQ: 53.16

Nicox's Days Payable declined from Jun. 2023 (559.21) to Jun. 2024 (0.00). It may suggest that Nicox accelerated paying its suppliers.

Nicox Days Payable Historical Data

The historical data trend for Nicox's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nicox Days Payable Chart

Nicox Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

1,205.02

892.88

820.57

62.36

49.93

Nicox Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Days Payable	Get a 7-Day Free Trial															792.40	35.17	559.21	31.59	-

Competitive Comparison of Nicox's Days Payable

For the Biotechnology subindustry, Nicox's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nicox's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nicox's Days Payable distribution charts can be found below:

* The bar in red indicates where Nicox's Days Payable falls into.

Nicox Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Nicox's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (2.537	+	2.499)	/	2 )	/	18.406	*	365
=	2.518					/	18.406	*	365
=	49.93

Nicox's Days Payable for the quarter that ended in Jun. 2024 is calculated as:

	Days Payable (Q: Jun. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2023 )	+	Accounts Payable (Q: Jun. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Jun. 2024 )	*	Days in Period
=	( (2.499	+	1.58)	/	2 )	/	0	*	365 / 2
=	2.0395					/	0	*	365 / 2
=	N/A

Nicox Days Payable Related Terms

Thank you for viewing the detailed overview of Nicox's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Nicox Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (LTS:0RCQ) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

NICXF:USA ALCOX:France NXOA:Germany NXOA:Germany

Address

Rue Evariste Galois, Emerald Square, Batiment C, Sundesk Sophia Antipolis, Biot, FRA, 06410

Website

https://www.nicox.com

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Its lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Its first product, VYZULTA in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE in allergic conjunctivitis, licensed in multiple geographies.

Nicox Headlines

No Headlines